These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30605381)

  • 21. Asparaginase and MOPP treatment of dogs with lymphoma.
    Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
    J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
    Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
    J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
    J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
    Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
    Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
    Wang SL; Lee JJ; Liao AT
    Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
    Wilder RB; Rodriguez MA; Tucker SL; Ha CS; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):743-9. PubMed ID: 11395243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas.
    Childress MO; Ramos-Vara JA; Ruple A
    J Am Vet Med Assoc; 2016 Nov; 249(9):1067-1078. PubMed ID: 27767437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of mitoxantrone in non-Hodgkin's lymphoma.
    Armitage JO
    Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
    Childress MO; Ramos-Vara JA; Ruple A
    Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of chemotherapy for the treatment of very elderly dogs with multicentric lymphoma.
    Moore AS; Frimberger AE
    J Am Vet Med Assoc; 2018 Apr; 252(7):852-859. PubMed ID: 29553895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
    J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma.
    Perry JA; Thamm DH; Eickhoff J; Avery AC; Dow SW
    Vet Comp Oncol; 2011 Mar; 9(1):55-64. PubMed ID: 21303454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
    Tirelli U; Errante D; Van Glabbeke M; Teodorovic I; Kluin-Nelemans JC; Thomas J; Bron D; Rosti G; Somers R; Zagonel V; Noordijk EM
    J Clin Oncol; 1998 Jan; 16(1):27-34. PubMed ID: 9440719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
    Lurie DM; Gordon IK; Théon AP; Rodriguez CO; Suter SE; Kent MS
    J Vet Intern Med; 2009; 23(5):1064-70. PubMed ID: 19627472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
    Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.